KOL = Key Opinion Leader The window to shape the oral GLP1 market is open nowand it will not remain open for long
Credit where it's due: this piece leans on the 2026 creatine + GLP-1 perspective from Darren Candow, Scott Forbes, and Chad Kerksick, and on the muscle-protein-synthesis work of Nicholas Burd and Stuart Phillips
[DOI] [PubMed] [Google Scholar] 150.Ping X., Junqing J., Junfeng J., Enjin J
PGC1A regulates the IRS1:IRS2 ratio during fasting to influence hepatic metabolism downstream of insulin
Viss laboratoriestd finns, men kliniska data p hrda utfall r begrnsade
Yet by 20252026, the sector faced a sharp pivot as FDA actions resolved shortages, curtailed large-scale compounding, and issued warning letters targeting misleading marketing claims